|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Subunits Interact Cooperatively in Switching G Protein-Coupled Receptor-to-Effector Specificity
7TM Pharma, Hoersholm, Denmark (E.K., L.M., P.K.N., R.J.); Ernest Gallo Clinic and Research Center, University of California, San Francisco, Emeryville, California (L.M., M.W., J.L.W.); Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland (J.E., G.M.); and Laboratory for Molecular Pharmacology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark (A.H., M.M.R.)
Numerous studies have attested to the importance of the extreme C terminus of G protein
subunits in determining their selectivity of receptor recognition. We have previously reported that a highly conserved glycine residue within linker I is important for constraining the fidelity of receptor recognition by G
q proteins. Herein, we explored whether both modules (linker I and extreme C terminus) interact cooperatively in switching G protein-coupled receptor (GPCR)-to-effector specificity and created as models mutant G
q proteins in which glycine was replaced with various amino acids and the C-terminal five G
q residues with the corresponding G
i or G
s sequence. Coupling properties of the mutated G
q proteins were determined after coexpression with a panel of 13 Gi-and Gs -selective receptors and compared with those of G
proteins modified in only one module. G
proteins modified in both modules are significantly more efficacious in channeling non-Gq -selective receptors to Gq-mediated signaling events compare with those containing each module alone. Additive effects of both modules were observed even if individual modules lacked an effect on GPCR-to-effector specificity. Dually modified G
proteins were also superior in conferring high-affinity agonist sites onto a coexpressed GPCR in the absence, but not in the presence, of guanine nucleotides. Together, our data suggest that receptor-G protein coupling selectivity involves cooperative interactions between the extreme C terminus and linker I of G
proteins and that distinct determinants of selectivity exist for individual receptors.
Address correspondence to: Dr. Evi Kostenis, 7TM Pharma, Fremtidsvej 3, 2970 Hoersholm, Denmark. E-mail: ek{at}7tm.com
This article has been cited by other articles:
![]() |
M. Vrecl, P. K. Norregaard, D. L.C. Almholt, L. Elster, A. Pogacnik, and A. Heding {beta}-Arrestin-Based Bret2 Screening Assay for the "Non"-{beta}-Arrestin Binding CB1 Receptor J Biomol Screen, April 1, 2009; 14(4): 371 - 380. [Abstract] [PDF] |
||||
![]() |
R. Schroder, N. Merten, J. M. Mathiesen, L. Martini, A. Kruljac-Letunic, F. Krop, A. Blaukat, Y. Fang, E. Tran, T. Ulven, et al. The C-terminal Tail of CRTH2 Is a Key Molecular Determinant That Constrains G{alpha}i and Downstream Signaling Cascade Activation J. Biol. Chem., January 9, 2009; 284(2): 1324 - 1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Stoddart, N. J. Smith, L. Jenkins, A. J. Brown, and G. Milligan Conserved Polar Residues in Transmembrane Domains V, VI, and VII of Free Fatty Acid Receptor 2 and Free Fatty Acid Receptor 3 Are Required for the Binding and Function of Short Chain Fatty Acids J. Biol. Chem., November 21, 2008; 283(47): 32913 - 32924. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Krietsch, M. S. Fernandes, J. Kero, R. Losel, M. Heyens, E. W.-F. Lam, I. Huhtaniemi, J. J. Brosens, and B. Gellersen Human Homologs of the Putative G Protein-Coupled Membrane Progestin Receptors (mPR{alpha}, {beta}, and {gamma}) Localize to the Endoplasmic Reticulum and Are Not Activated by Progesterone Mol. Endocrinol., December 1, 2006; 20(12): 3146 - 3164. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Mathiesen, A. Christopoulos, T. Ulven, J. F. Royer, M. Campillo, A. Heinemann, L. Pardo, and E. Kostenis On the Mechanism of Interaction of Potent Surmountable and Insurmountable Antagonists with the Prostaglandin D2 Receptor CRTH2 Mol. Pharmacol., April 1, 2006; 69(4): 1441 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Mathiesen, T. Ulven, L. Martini, L. O. Gerlach, A. Heinemann, and E. Kostenis Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 Mol. Pharmacol., August 1, 2005; 68(2): 393 - 402. [Abstract] [Full Text] [PDF] |
||||